| CD82 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | CD82, 4F9, C33, GR15, IA4, KAI1, R2, SAR2, ST6, TSPAN27, CD82 molecule | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 600623 MGI: 104651 HomoloGene: 20512 GeneCards: CD82 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
CD82 (Cluster of Differentiation 82), or KAI1, is a human protein encoded by the CD82 gene.[5]
This metastasis suppressor gene product is a membrane glycoprotein that is a member of the tetraspanin/transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.[5]
Interactions
CD82 (gene) has been shown to interact with CD19,[6][7] CD63[8] and CD234.[9]
CD82 plays a key role in the development of endometriosis.[10]
See also
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000085117 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000027215 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- 1 2 "Entrez Gene: CD82 CD82 molecule".
- ↑ Imai T, Kakizaki M, Nishimura M, Yoshie O (August 1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82". Journal of Immunology. 155 (3): 1229–39. doi:10.4049/jimmunol.155.3.1229. PMID 7636191. S2CID 32942467.
- ↑ Horváth G, Serru V, Clay D, Billard M, Boucheix C, Rubinstein E (November 1998). "CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82". The Journal of Biological Chemistry. 273 (46): 30537–43. doi:10.1074/jbc.273.46.30537. PMID 9804823.
- ↑ Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P (October 1998). "The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules". Journal of Immunology. 161 (7): 3282–91. doi:10.4049/jimmunol.161.7.3282. PMID 9759843.
- ↑ Hur J, Choi JI, Lee H, Nham P, Kim TW, Chae CW, et al. (April 2016). "CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages". Cell Stem Cell. 18 (4): 508–21. doi:10.1016/j.stem.2016.01.013. PMID 26996598.
- ↑ Timologou A, Zafrakas M, Grimbizis G, Miliaras D, Kotronis K, Stamatopoulos P, Tarlatzis B (February 2016). "Immunohistochemical expression pattern of metastasis suppressors". European Journal of Obstetrics & Gynecology and Reproductive Biology. 199: 110–115. doi:10.1016/j.ejogrb.2016.02.004. PMID 26918694.
Further reading
- Baek SH (July 2006). "A novel link between SUMO modification and cancer metastasis". Cell Cycle. 5 (14): 1492–5. doi:10.4161/cc.5.14.3008. PMID 16861889.
- Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, et al. (November 1992). "C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63". Journal of Immunology. 149 (9): 2879–86. doi:10.4049/jimmunol.149.9.2879. PMID 1401919. S2CID 21935007.
- Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, et al. (June 1992). "Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11". Cancer Research. 52 (12): 3486–90. PMID 1596907.
- Gaugitsch HW, Hofer E, Huber NE, Schnabl E, Baumruker T (February 1991). "A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23". European Journal of Immunology. 21 (2): 377–83. doi:10.1002/eji.1830210219. PMID 1842498. S2CID 423800.
- Ichikawa T, Ichikawa Y, Isaacs JT (July 1991). "Genetic factors and suppression of metastatic ability of prostatic cancer". Cancer Research. 51 (14): 3788–92. PMID 2065333.
- Imai T, Kakizaki M, Nishimura M, Yoshie O (August 1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82". Journal of Immunology. 155 (3): 1229–39. doi:10.4049/jimmunol.155.3.1229. PMID 7636191. S2CID 32942467.
- Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC (May 1995). "KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2". Science. 268 (5212): 884–6. Bibcode:1995Sci...268..884D. doi:10.1126/science.7754374. PMID 7754374.
- Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME (September 1996). "Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29)". Journal of Immunology. 157 (5): 2039–47. doi:10.4049/jimmunol.157.5.2039. PMID 8757325.
- Szöllósi J, Horejsí V, Bene L, Angelisová P, Damjanovich S (October 1996). "Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY". Journal of Immunology. 157 (7): 2939–46. doi:10.4049/jimmunol.157.7.2939. PMID 8816400.
- Dong JT, Isaacs WB, Barrett JC, Isaacs JT (April 1997). "Genomic organization of the human KAI1 metastasis-suppressor gene". Genomics. 41 (1): 25–32. doi:10.1006/geno.1997.4618. PMID 9126478.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P (October 1998). "The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules". Journal of Immunology. 161 (7): 3282–91. doi:10.4049/jimmunol.161.7.3282. PMID 9759843.
- Horváth G, Serru V, Clay D, Billard M, Boucheix C, Rubinstein E (November 1998). "CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82". The Journal of Biological Chemistry. 273 (46): 30537–43. doi:10.1074/jbc.273.46.30537. PMID 9804823.
- Serru V, Le Naour F, Billard M, Azorsa DO, Lanza F, Boucheix C, Rubinstein E (May 1999). "Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions". The Biochemical Journal. 340 ( Pt 1) (1): 103–11. doi:10.1042/0264-6021:3400103. PMC 1220227. PMID 10229664.
- Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC (November 1999). "Loss of KAI1 expression in the progression of colorectal cancer". Cancer Research. 59 (22): 5724–31. PMID 10582691.
- Shibagaki N, Hanada K, Yamashita H, Shimada S, Hamada H (December 1999). "Overexpression of CD82 on human T cells enhances LFA-1 / ICAM-1-mediated cell-cell adhesion: functional association between CD82 and LFA-1 in T cell activation". European Journal of Immunology. 29 (12): 4081–91. doi:10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.0.CO;2-I. PMID 10602019.
- Nakamura K, Mitamura T, Takahashi T, Kobayashi T, Mekada E (June 2000). "Importance of the major extracellular domain of CD9 and the epidermal growth factor (EGF)-like domain of heparin-binding EGF-like growth factor for up-regulation of binding and activity". The Journal of Biological Chemistry. 275 (24): 18284–90. doi:10.1074/jbc.M907971199. PMID 10749879.
- Odintsova E, Sugiura T, Berditchevski F (August 2000). "Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1". Current Biology. 10 (16): 1009–12. doi:10.1016/S0960-9822(00)00652-7. PMID 10985391. S2CID 15731587.
- Ono M, Handa K, Withers DA, Hakomori S (December 2000). "Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, alpha5-CD82 glycosylation complex in ldlD 14 cells". Biochemical and Biophysical Research Communications. 279 (3): 744–50. doi:10.1006/bbrc.2000.4030. PMID 11162423.
External links
- CD82+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Human CD82 genome location and CD82 gene details page in the UCSC Genome Browser.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.